Cellinfinity Bio
Developer of engineered cell-therapy technologies that apply directed-evolution and genetic engineering to reprogram immune cells in vivo and ex vivo for treatment of solid tumors. The organization advances preclinical candidates for both in vivo gene-delivery–based T cell reprogramming and autologous CAR-T therapies, and pursues IND-enabling development and collaborations.
Industries
Nr. of Employees
small (1-50)
Cellinfinity Bio
Products
In vivo CAR-T therapy candidate (preclinical)
A preclinical candidate that uses in vivo gene-delivery to generate tumor-targeting T cells in patients, incorporating novel target selection and genetic enhancements for solid tumors.
Autologous CAR-T therapy candidate (preclinical)
A preclinical autologous CAR-T candidate that incorporates novel antigen targeting and cellular enhancements intended for solid-tumor indications.
Supercharged In Vivo Cell Therapy™
A simplified in vivo CAR-T cell therapy platform that allows the patient's own body to produce the therapy without the need for complex manufacturing or lymphodepletion.
In vivo CAR-T therapy candidate (preclinical)
A preclinical candidate that uses in vivo gene-delivery to generate tumor-targeting T cells in patients, incorporating novel target selection and genetic enhancements for solid tumors.
Autologous CAR-T therapy candidate (preclinical)
A preclinical autologous CAR-T candidate that incorporates novel antigen targeting and cellular enhancements intended for solid-tumor indications.
Supercharged In Vivo Cell Therapy™
A simplified in vivo CAR-T cell therapy platform that allows the patient's own body to produce the therapy without the need for complex manufacturing or lymphodepletion.
Services
Partnerships to access preclinical cell-therapy candidates and to support lead optimization and IND-enabling activities.
Partnerships to access preclinical cell-therapy candidates and to support lead optimization and IND-enabling activities.
Expertise Areas
- Directed evolution for cell therapy
- In vivo gene delivery and in situ immune-cell engineering
- CAR design and T cell engineering
- Tumor-target antigen discovery
Key Technologies
- Directed-evolution platforms
- AAV-mediated gene delivery
- Transposon-based gene delivery (Sleeping Beauty)
- mRNA-encoded transposase delivery
News & Updates
Announcement of publication and exclusive licensing of a novel CAR-design technology.
Announcement of publication and exclusive licensing of a novel gene-delivery technology.
Announcement regarding publication and licensing of a technology for directed evolution of cells to improve adoptive cell therapy.
Recipient of the 2022 Future Innovator Prize as noted in press coverage.
Announcement of publication and exclusive licensing of a novel CAR-design technology.
Announcement of publication and exclusive licensing of a novel gene-delivery technology.
Announcement regarding publication and licensing of a technology for directed evolution of cells to improve adoptive cell therapy.
Recipient of the 2022 Future Innovator Prize as noted in press coverage.